Current management of glaucoma

Lusthaus, Jed; Goldberg, Ivan

doi:10.5694/mja2.50020

ARTICLE
AUTHORS
REFERENCES

Topics

Eye diseases

Surgical procedures, operative

Summary

Glaucoma is an irreversible progressive optic neuropathy, for which the major proven treatment is to lower the intraocular pressure (IOP).
Five groups of IOP‐lowering eye drops have varying mechanisms of action. Some drops, such as β‐blockers and α‐2 agonists, have potentially serious systemic side effects. Acetazolamide is the only available oral agent; it is effective at lowering IOP, but significant side effects relegate its use usually to refractory glaucoma.
Two new eye drops, netarsudil and latanoprostene bunod, have recently been approved by the United States Food and Drug Administration. Both have novel IOP‐lowering mechanisms and target the conventional aqueous outflow system.
Selective laser trabeculoplasty is a gentle treatment that enhances conventional aqueous outflow. It may be used as an initial treatment, as a substitute for eye drops, or to delay glaucoma drainage surgery.
Recent advancements in glaucoma surgery have seen an influx of minimally invasive glaucoma surgery devices, which are being used more frequently and earlier on in the treatment paradigm. As limited long term data are available, trabeculectomy remains the gold standard IOP‐lowering procedure. Improvements in drug delivery are on the horizon. Drug‐eluting devices and implants are able to deliver the drug closer to the receptors for an extended period of time. This will improve treatment adherence and efficacy, which are major limitations with current medical therapy.

1 University of Sydney, Sydney, NSW
2 Sydney Hospital and Sydney Eye Hospital, Sydney, NSW

Correspondence: eyeGoldberg@gmail.com

Competing interests:

No relevant disclosures.

1. Gordon MO, Kass MA. The Ocular Hypertension Treatment Study: design and baseline description of the participants. Arch Ophthalmol 1999; 117: 573–583.
2. Leske MC, Heijl A, Hyman L, et al. Early Manifest Glaucoma Trial: design and baseline data. Ophthalmology 1999; 106: 2144–2153.
3. Ederer F, Gaasterland DE, Sullivan EK, et al. The Advanced Glaucoma Intervention Study (AGIS): 1. Study design and methods and baseline characteristics of study patients. Control Clin Trials 1994; 15: 299–325.
4. Musch DC, Lichter PR, Guire KE, et al. The Collaborative Initial Glaucoma Treatment Study: study design, methods, and baseline characteristics of enrolled patients. Ophthalmology 1999; 106: 653–662.
5. Anderson DR. Collaborative normal tension glaucoma study. Curr Opin Ophthalmol 2003; 14: 86–90.
6. Leske MC. The epidemiology of open‐angle glaucoma: a review. Am J Epidemiol 1983; 118: 166–191.
7. Lusthaus JA, Goldberg I. Emerging drugs to treat glaucoma: targeting prostaglandin F and E receptors. Expert Opin Emerg Drugs 2016; 21: 117–128.
8. Mantravadi AV, Vadhar N. Glaucoma. Prim Care Clin Office Pract 2015; 42: 437–449.
9. Kingman S. Glaucoma is second leading cause of blindness globally. Bull World Health Organ 2004; 82: 887–888.
10. Tielsch JM, Sommer A, Katz J, et al. Racial variations in the prevalence of primary open‐angle glaucoma. The Baltimore Eye Survey. JAMA 1991; 266: 369–374.
11. Mitchell P, Smith W, Attebo K, Healey PR. Prevalence of open‐angle glaucoma in Australia. The Blue Mountains Eye Study. Ophthalmology 1996; 103: 1661–1669.
12. Wensor MD, McCarthy CA, Stanislavsky YL, et al. The prevalence of glaucoma in the Melbourne Visual Impairment Project. Ophthalmology 1998; 105: 733–739.
13. Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol 2006; 90: 262–267.
14. Nucci C, Martucci A, Giannini C, et al. Neuroprotective agents in the management of glaucoma. Eye 2018; 32: 938–945.
15. Konstas AGP, Topouzis F, Leliopoulou O, et al. 24‐hour intraocular pressure control with maximum medical therapy compared with surgery in patients with advanced open‐angle glaucoma. Ophthalmology 2006; 113: 761.e1–765.e1.
16. Stein JD, Ayyagari P, Sloan FA, et al. Rates of glaucoma medication utilization among persons with primary open‐angle glaucoma 1992 to 2002. Ophthalmology 2008; 115: 1315–1319.
17. Winkler N, Fautsch MP. Effects of prostaglandin analogues on aqueous humor outflow pathways. J Ocul Pharmacol Ther 2014; 30: 102–109.
18. Johnstone MA, Albert DM. Prostaglandin‐induced hair growth. Surv Ophthalmol 2002; 47 (Suppl): S185–S202.
19. Sakata R, Shirato S, Miyata K, et al. Incidence of deepening of the upper eyelid sulcus in prostaglandin‐associated periorbitopathy with a latanoprost ophthalmic solution. Eye 2014; 28: 1446–1451.
20. Alm A, Grierson I, Shields MB. Side effects associated with prostaglandin analog therapy. Surv Ophthalmol 2008; 53: S93–S105.
21. Aptel F, Cucherat M, Denis P. Efficacy and tolerability of prostaglandin analogs: a meta‐analysis of randomized controlled clinical trials. J Glaucoma 2008; 17: 667–673.
22. Lin JC. The use of ocular hypotensive drugs for glaucoma treatment: changing trend in Taiwan from 1997 to 2007. J Glaucoma 2015; 24: 364–371.
23. Sambhara DS, Aref AA. Glaucoma management: relative value and place in therapy of available drug treatments. Ther Adv Chronic Dis 2014; 5: 30–43.
24. Kaiser HJ, Schoetzau A, Stump D, et al. Blood flow velocities of the extraocular vessels in patients with high‐tension and normal‐tension primary open‐angle glaucoma. Am J Ophthalmol 1997; 123: 320–327.
25. Lusthaus JA, Goldberg I. Brimonidine and brinzolamide for treating glaucoma and ocular hypertension; a safety evaluation. Expert Opinion on Drug Safety 2017; 16: 1071–1078.
26. Arthur S, Cantor LB. Update on the role of alpha‐agonists in glaucoma management. Exp Eye Res 2011; 93: 271–283.
27. Nguyen QH. Combination of brinzolamide and brimonidine for glaucoma and ocular hypertension: critical appraisal and patient focus. Patient Prefer Adherence 2014; 8: 853–864.
28. Toris CB, Camras CB, Yablonski ME. Effects of brimonidine on aqueous humor dynamics in human eyes. Arch Ophthalmol 1995; 113: 1514–1517.
29. Silver LH. Clinical efficacy and safety of brinzolamide (Azopt), a new topical carbonic anhydrase inhibitor for primary open‐angle glaucoma and ocular hypertension. Am J Ophthalmol 1998; 126: 400–408.
30. Van der Valk R, Webers CAB, Schouten JS, et al. Intraocular pressure‐lowering effects of all commonly used glaucoma drugs: a meta‐analysis of randomized clinical trials. Ophthalmology 2005; 112: 1177–1185.
31. Hu CY, Lee BJ, Cheng HF, et al. Acetazolamide‐related life‐threatening hypophosphatemia in a glaucoma patient. J Glaucoma 2015; 24: e31–e33.
32. McLaren NC, Moroi SE. Clinical implications of pharmacogenetics for glaucoma therapeutics. Pharmacogenomics J 2003; 3: 197–201.
33. Okeke CO, Quigley HA, Jampel HD, et al. Adherence with topical glaucoma medication monitored electronically. Ophthalmology 2009; 116: 191–199.
34. Kosoko O, Quigley HA, Vitale S, et al. Risk factors for non‐compliance with glaucoma follow‐up visits. Ophthalmology 1998; 105: 2105–2111.
35. McVeigh KA, Vakros G. The eye drop chart: a pilot study for improving administration of and compliance with topical treatments in glaucoma patients. Clin Ophthalmol 2015; 9: 813–819.
36. Inoue K, Soeda S, Tomita G. Comparison of latanoprost/timolol with carbonic anhydrase inhibitor and dorzolamide/timolol with prostaglandin analog in the treatment of glaucoma. J Ophthalmol 2014; 2014: 975429.
37. Skalicky SE, Goldberg I, McCluskey P. Ocular surface disease and quality of life in patients with glaucoma. Am J Ophthalmol 2012; 153: 1.e2–9.e2.
38. Latina M, Tumbocon JA. Selective laser trabeculoplasty: a new treatment option for open angle glaucoma. Curr Opin Ophthalmol 2002; 13: 94–96.
39. McAlinden C. Selective laser trabeculoplasty (SLT) vs other treatment modalities for glaucoma: systematic review. Eye 2014; 28: 249–258.
40. Fan Gaskin JC, Sandhu SS, Walland MJ. Victorian trabeculectomy audit. Clin Exp Ophthalmol 2017; 45: 695–700.
41. Kirwan JF, Lockwood AJ, Shah P, et al. Trabeculectomy in the 21st century: a multicenter analysis. Ophthalmology 2013; 120: 2532–2539.
42. Gedde SJ, Schiffman JC, Feuer WJ, et al. Treatment outcomes in the tube versus trabeculectomy (TVT) study after five years of follow‐up. Am J Ophthalmol 2012; 153: 789–803.
43. Lavia C, Dallorto L, Maule M, et al. Minimally‐invasive glaucoma surgeries (MIGS) for open angle glaucoma: a systematic review and meta‐analysis. PLoS One 2017; 12: e0183142.
44. Saheb H, Ahmed II. Micro‐invasive glaucoma surgery: current perspectives and future directions. Curr Opin Ophthalmol 2012; 23: 96–104.
45. Chaudhary A, Salinas L, Guidotti J, et al. XEN Gel Implant: a new surgical approach in glaucoma. Expert Rev Med Devices 2018; 15: 47–59.
46. Martin KR, Broadway DC. Cyclodiode laser therapy for painful, blind glaucomatous eyes. Br J Ophthalmol 2001; 85: 474–476.
47. Aquino MC, Barton K, Tan AM, et al. Micropulse versus continuous wave transcleral diode cyclophotocoagulation in refractory glaucoma: a randomized exploratory study. Clin Exp Ophthalmol 2015; 43: 40–46.
48. Azuara‐Blanco A, Burr J, Ramsay C, et al. Effectiveness of early lens extraction for the treatment of primary angle‐closure glaucoma (EAGLE): a randomised controlled trial. Lancet 2016; 388: 1389–1397.
49. Bacharach J, Dubiner HB, Levy B, et al. Double‐masked, randomized, dose‐response study of AR‐13324 versus latanoprost in patients with elevated intraocular pressure. Ophthalmology 2015; 122: 302–307.
50. Weinreb RN, Ong T, Scassellati Sforzolini B, et al. A randomized, controlled comparison of latanoprostene bunod and latanoprost 0.005% in the treatment of ocular hypertension and open angle glaucoma: the VOYAGER study. Ophthalmology 2015; 99: 738–745.

Online responses are no longer available. Please refer to our instructions for authors page for more information.

Current management of glaucoma

Topics

Summary

Author

Comment

Do you have any competing interests to declare? *